Diagnosis and Management of Multiple Sclerosis in Children

Area of Science:

• Pediatric Neurology
• Neuroimmunology
• Multiple Sclerosis Therapeutics

Background:

• Multiple sclerosis (MS) in children, or pediatric MS, presents unique management challenges.
• Established adult MS treatments, including first-line therapies, are increasingly recognized as safe for pediatric use.
• Treatment adjustments are common in pediatric MS, necessitating careful monitoring and experienced care.

Purpose of the Study:

• To review the safety and tolerability of disease-modifying therapies (DMTs) in children with MS.
• To highlight the prevalence of treatment alterations and the need for specialized pediatric MS centers.
• To assess the current evidence regarding second-line therapies and the unexplored potential of oral agents in pediatric MS.

Main Methods:

• Review of existing evidence on disease-modifying treatments for pediatric multiple sclerosis.
• Analysis of safety, tolerability, and treatment alteration patterns in children with MS.
• Comparison of pediatric MS treatment outcomes with those observed in adult MS patients.

Main Results:

• Disease-modifying therapies, including first-line treatments, demonstrate good safety and tolerability in pediatric MS.
• Treatment failure and subsequent therapy alteration are highly prevalent in pediatric MS patients.
• Children with MS undergoing immunomodulatory treatment experience side effects comparable to adult patients.

Conclusions:

• Current first- and second-line therapies are generally safe and well-tolerated in pediatric multiple sclerosis.
• Specialized centers are essential for managing the complexities and frequent treatment changes in pediatric MS.
• Further large-scale, long-term prospective studies are required to fully elucidate the benefits and risks of pediatric MS therapies, especially oral agents.